WP-1302 is under clinical development by Worg Pharmaceuticals Hangzhou and currently in Phase II for Graves Diseases. According to GlobalData, Phase II drugs for Graves Diseases does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the WP-1302 LoA Report. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WP-1302 overview
WP-1302 is under development for the treatment of Graves' disease and unspecified indication. The drug candidate is peptide vaccine that is administered intradermally and subcutaneously. ATX-GD-59 is developed based on apitope technology platform. The therapy is specifically designed from naturally occurring antigenic proteins to selectively inhibit the immune system's harmful attack on the body while preserving the normal immune response to harmful antigens.
Worg Pharmaceuticals Hangzhou overview
Worg Pharmaceuticals is a clinical-stage biopharmaceutical company developing new treatments for allergy and other diseases with high unmet medical needs and considerable commercial potential. It is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of WP-1302’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
